The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
argenx SE Common 04016X101 11,509 71,700 SH   SOLE   71,700 0 0
ArQule, Inc. Common 04269E107 21,840 1,094,210 SH   SOLE   1,094,210 0 0
Autolus Therapeutics Limited Common 05280R100 525 39,740 SH   SOLE   39,740 0 0
CytomX Therapeutics, Inc. Common 23284F105 7,109 855,437 SH   SOLE   855,437 0 0
Deciphera Pharmaceuticals, Inc. Common 24344T101 13,417 215,570 SH   SOLE   215,570 0 0
Epizyme, Inc. Common 29428V104 57,356 2,331,534 SH   SOLE   2,331,534 0 0
G1 Therapeutics, Inc. Common 3621LQ109 37,631 1,423,794 SH   SOLE   1,423,794 0 0
Harpoon Therapeutics, Inc. Common 41358P106 57,658 3,898,422 SH   SOLE   3,898,422 0 0
MEI Pharma, Inc. Common 552798202 15,500 6,250,000 SH   SOLE   6,250,000 0 0
Sunesis Pharmaceuticals, Inc. Common 867328700 949 2,809,912 SH   SOLE   2,809,912 0 0
TCR2 Therapeutics, Inc. Common 87808K106 48,138 3,370,982 SH   SOLE   3,370,982 0 0
YmAbs Therapeutics, Inc. Common 984241109 10,540 337,291 SH   SOLE   337,291 0 0